Who Paid My Doc
David Fitz-Patrick
Honolulu, HI Medical Doctor
NPI 1275531154 CMS profile 148104
1585 Kapiolani Blvd, Suite 1500, Honolulu, HI 96814
General payments
$502
Research payments
$262,759
Ownership & investment interest
$0
Research they led as principal investigator
$26,374,134
Through program year 2025, David Fitz-Patrick of Honolulu, HI is reported in the CMS Open Payments database as having received $502 across 7 general payments and $262,759 in research payments paid to them. Separately, studies naming them as principal investigator received $26,374,134 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | Research | $6,400 | 2 | |
| 2024 | General | $28 | 1 | |
| 2024 | Research | $3,820 | 2 | |
| 2023 | General | $15 | 1 | |
| 2023 | Research | $3,915 | 4 | |
| 2022 | General | $15 | 1 | |
| 2022 | Research | $13,540 | 8 | |
| 2021 | General | $35 | 2 | |
| 2021 | Research | $9,356 | 5 | |
| 2020 | Research | $85,136 | 5 | |
| 2019 | General | $409 | 2 | |
| 2019 | Research | $140,593 | 5 |
Beside peers
- David Fitz-Patrick
- Hawaii median
- Middle half of Hawaii
- National median
In program year 2025, general payments to David Fitz-Patrick were reported at $0. Among 3,634 Hawaii profiles paid that year, the median was $183 and the middle half received between $63 and $652.
Show as a table
| Year | David Fitz-Patrick | Hawaii median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $409 | $190 | $62–$622 | $163 |
| 2020 | $0 | $125 | $43–$352 | $114 |
| 2021 | $35 | $150 | $51–$524 | $132 |
| 2022 | $15 | $172 | $58–$577 | $149 |
| 2023 | $15 | $166 | $61–$537 | $160 |
| 2024 | $28 | $172 | $59–$611 | $164 |
| 2025 | $0 | $183 | $63–$652 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 28 drugsPart D claims
1,277
Drug cost
$709,875
Branded share of claims
49.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 153 | $332,685 | |
| Prolia Denosumab | Brand | 45 | $78,638 | |
| Jardiance Empagliflozin | Brand | 45 | $60,211 | |
| Sandostatin Lar Depot Octreotide Acetate,mi-Spheres | Brand | 11 | $49,429 | |
| Mounjaro Tirzepatide | Brand | 23 | $44,850 | |
| Januvia Sitagliptin Phosphate | Brand | 26 | $35,572 | |
| Farxiga Dapagliflozin Propanediol | Brand | 17 | $27,923 | |
| Nutropin Aq Nuspin Somatropin | Brand | 19 | $17,315 | |
| Tresiba Flextouch U-100 Insulin Degludec | Brand | 24 | $16,920 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 37 | $6,092 |
The 10 drugs with the highest cost, of 28 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 15 billing codesPaid by Medicare
$21,538
Medicare patients
185
Services billed
542
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 60% | |
| Chronic kidney disease | 45% | |
| Osteoporosis | 37% | |
| Arthritis | 33% | |
| Ischemic heart disease | 24% | |
| Cancer | 18% | |
| Atrial fibrillation | 13% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
38 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.